Article
On-demand use of a phosphodiesterase type-5 inhibitor did not affect prostatic or urinary outcomes of therapy for BPH, a post hoc analysis of a large randomized trial showed.
FDA Updates in Urology: January 2025
Identifying Patients with Intermediate Risk in NMIBC
Urologic Cancer Facts and Updates for World Cancer Day 2025
Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
AI and wearables: The new age of smart sex
Hundreds of future urologists celebrate Urology Match Day 2025